Mehmet K. Samur, PhD | Authors


Analysis Explores Impact of Increased Point Mutations With High-Dose Melphalan in Myeloma

December 28, 2020

Mehmet K. Samur, PhD, discusses findings from an analysis evaluating high-dose melphalan followed by autologous stem cell transplant as treatment of patients with multiple myeloma compared with the standard of care treatment regimen lenalidomide, bortezomib, and dexamethasone alone.